“Breaking News: SELLAS Life Sciences Reports Promising Results from Interim Analysis of Phase 3 REGAL Trial for GPS Treatment in Acute Myeloid Leukemia”
REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification In exciting news for the medical community, REGAL has announced the successful passing of the event-driven interim analysis for their clinical trial, which required reaching 60 deaths to…